Search Results - "Antal, J.M."

2 Oral: Preliminary results from SEACRAFT-1: An open-label study of naporafenib with trametinib in patients with locally advanced unresectable or metastatic solid tumor malignancies with RAS Q61X mutations by Fontana, E., Spira, A.I., McKean, M., Lee, J., Chau, N., Winquist, E., Kim, I., Hong, S.H., Van Tine, B.A., Fawole, A., Shoemaker, R., Cui, Y., Sutton, R., Antal, J.M., Morris, S.R., Hong, D.S.

Get full text

Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial by Weiss, J.M., Csoszi, T., Maglakelidze, M., Hoyer, R.J., Beck, J.T., Domine Gomez, M., Lowczak, A., Aljumaily, R., Rocha Lima, C.M., Boccia, R.V., Hanna, W., Nikolinakos, P., Chiu, V.K., Owonikoko, T.K., Schuster, S.R., Hussein, M.A., Richards, D.A., Sawrycki, P., Bulat, I., Hamm, J.T., Hart, L.L., Adler, S., Antal, J.M., Lai, A.Y., Sorrentino, J.A., Yang, Z., Malik, R.K., Morris, S.R., Roberts, P.J., Dragnev, K.H.

“…Chemotherapy-induced damage of hematopoietic stem and progenitor cells (HSPC) causes multi-lineage myelosuppression. Trilaciclib is an intravenous CDK4/6…”
Get full text

1742PD - Trilaciclib (T) decreases myelosuppression in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy plus atezolizumab by Daniel, D., Kuchava, V., Bondarenko, I., Ivashchuk, O., Spigel, D., Dasgupta, A., Reddy, S., Melkadze, T., Jaal, J., Kudaba, I., Hart, L., Matitashvili, A., Koynov, K.D., Yang, Z., Wolfe, S.G., Malik, R., Morris, S.R., Antal, J.M., Goldschmidt, J.

“…Chemotherapy (chemo)-induced damage of hematopoietic stem and progenitor cells (HSPC) causes multi-lineage myelosuppression. Current supportive therapies are…”
Get full text

Trilaciclib (T) decreases myelosuppression in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy plus atezolizumab by Daniel, D., Kuchava, V., Bondarenko, I., Ivashchuk, O., Spigel, D., Dasgupta, A., Reddy, S., Melkadze, T., Jaal, J., Kudaba, I., Hart, L., Matitashvili, A., Koynov, K.D., Yang, Z., Wolfe, S.G., Malik, R., Morris, S.R., Antal, J.M., Goldschmidt, J.

Get full text

Trilaciclib (trila) preserves and enhances immune system function in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy by Sorrentino, J.A., Lai, A., Weiss, J.M., Dragnev, K.H., Owonikoko, T.K., Adler, S., Antal, J.M., Malik, R.K., Roberts, P.J.

Get full text

Trilaciclib (T) decreases multi-lineage myelosuppression in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy by Dragnev, K.H., Owonikoko, T.K., Csoszi, T., Maglakelidze, M., Beck, J.T., Domine Gomez, M., Lowczak, A., Fulop, A., Hoyer, R.J., Hanna, W., Lowry, P., Aljumaily, R., Chiu, V.K., Bulat, I., Yang, Z., Roberts, P.J., Antal, J.M., Malik, R.K., Morris, S.R., Weiss, J.M.

Get full text